Biodexa Pharmaceuticals (BDRX) Notes Payables (2019 - 2025)
Biodexa Pharmaceuticals (BDRX) posted Notes Payables of $3.9 million for Q4 2025, up 6820.29% sequentially from $56029.9 in Q2 2025, and up 688.77% YoY from $491581.2 in Q4 2024.
Biodexa Pharmaceuticals (BDRX) Notes Payables (2019 - 2025) Analysis & Trends
Biodexa Pharmaceuticals has reported Notes Payables for 7 years, with the latest figure at $3.9 million in Q4 2025.
- Quarterly Notes Payables rose 688.77% year-over-year to $3.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.9 million (up 688.77% YoY) and the FY2025 annual result came in at $3.8 million, up 681.86% from the prior year.
- Notes Payables climbed to $3.9 million in Q4 2025 per BDRX's latest filing, from $56029.9 in the prior quarter.
- Over five years, Notes Payables peaked at $5.2 million in Q4 2023 and troughed at $56029.9 in Q2 2025.
- A 5-year average of $1.5 million and a median of $618515.5 in 2021 frame the typical range for Notes Payables.
- The sharpest annual moves came in 2023 and 2025: Notes Payables soared 5078.78% in 2023, then slumped 96.17% in 2025.
- Over 5 years, Notes Payables stood at $745449.9 in 2021, then sank by 86.63% to $99698.9 in 2022, then jumped by 5078.78% to $5.2 million in 2023, then sank by 90.48% to $491581.2 in 2024, then surged by 688.77% to $3.9 million in 2025.
- According to Business Quant data, Notes Payables over the past three periods registered $3.9 million, $56029.9, and $491581.2 for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Biodexa Pharmaceuticals | 63,168.17 | -11.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.88 Mn |
| Jun 30, 2025 | 56,029.92 |
| Dec 31, 2024 | 491,581.20 |
| Jun 30, 2024 | 1.46 Mn |
| Dec 31, 2023 | 5.16 Mn |
| Jun 30, 2023 | 455,496.19 |
| Dec 31, 2022 | 99,698.91 |
| Jun 30, 2022 | 195,193.70 |
| Dec 31, 2021 | 745,449.87 |
| Jun 30, 2021 | 2.27 Mn |
| Dec 31, 2020 | 2.06 Mn |
| Jun 30, 2020 | 1.43 Mn |
| Dec 31, 2019 | 853,721.34 |